– Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 –
– EO1001 is an irreversible pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) –
FOSTER CITY, Calif. And HANGZHOU, China and MENLO PARK, Calif., February 9, 2021 (GLOBE NEWSWIRE) – Apollomics, Inc.., an innovative biopharmaceutical company dedicated to the discovery and development of single and combination therapy therapies, and Edison Oncology Holding Corp. today announced that Apollomics has been granted worldwide rights except China, Hong Kong and Taiwan to develop and develop commercialization of EO1001. EO1001 is a protein tyrosine kinase inhibitor (TKI) that has shown an irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single active ingredient.
“We are excited to add EO1001 to our clinical development portfolio because of its pan-erbB inhibition and well-tolerated preclinical safety profile, making it a potential targeted therapy for the treatment of solid tumor cancers that overexpress EGFR and / or HER2 “said Sanjeev Redkar, PhD, co-founder and president of Apollomics. “In preclinical models, EO1001 is effective against mutations in both the intracellular and extracellular domains of EGFR and has shown activity in tumors that can invade the central nervous system. As we advance our pipeline for clinical development, we continue to seek out assets like EO1001 with well-defined mechanisms of action and differentiating attributes that we believe can make a difference for cancer patients worldwide. Looking ahead, Australia is filing a Clinical Trial Notification (CTN) application in Australia to initiate a clinical trial in the second quarter of this year. “
Under the terms of the agreement, Apollomics has exclusive rights to develop and commercialize EO1001 worldwide, except in China, Hong Kong and Taiwan. Edison Oncology receives a cash upfront payment and may receive potential milestone payments for development and sales, as well as tiered royalties on net sales. Apollomics will be responsible for all costs related to development, regulatory approvals and commercialization activities for EO1001 in the territories.
“Our extensive and successful preclinical work with EO1001 has led us to this collaboration with Apollomics, who will now bring the asset into clinical studies with their experienced development team. Over 90% of solid tumors overexpress erbB signaling pathways. With the data so far, we are confident that EO1001 has the potential to improve patient outcomes for patients with life-threatening cancers, ”concluded Jeffrey A. Bacha B. Chief Executive Officer of Edison Oncology.
EO1001 is a protein tyrosine kinase inhibitor (TKI) that has shown an irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single active ingredient. EO1001 is effective against mutations in the intracellular domain of EGFR that typically occur in diseases such as non-small cell lung cancer (NSCLC) including T790M, L858R and d746-750, and against mutations in the extracellular domain of EGFR, including EGFR variant III ( EGFRvIII) mutation that is characteristic of glioblastoma. In preclinical studies, EO1001 was well tolerated and demonstrated in vivo activity against treatment-resistant ErbB-driven tumors, including malignancies of the central nervous system.
About Edison Oncology
Edison Oncology was founded in 2018 by seasoned life science industry veterans to develop and commercialize new therapies to fight cancer. Edison Oncology uses a deep understanding of cancer biology and pharmacology to identify and develop underdeveloped drug candidates with the potential to overcome treatment resistance and improve survival outcomes and quality of life for cancer patients.
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company dedicated to the discovery and development of mono and combo oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several assets in development, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies for uncontrolled growth pathways. For more information, please visit www.apollomicsinc.com.
Edison Oncology Contacts:
Media and investor relations contact:
Amato and Partners, LLC
Investor Relations Counsel
Wilson W. Cheung
US media contact: